TY - JOUR
T1 - Comparison of Robot-Assisted Laparoscopic Partial Nephrectomy with Laparoscopic Cryoablation in the Treatment of Localised Renal Tumours: A Propensity Score-Matched Comparison of Long-Term Outcomes.
AU - Liu, HY
AU - Kang, CH
AU - Wang, HJ
AU - Chen, CH
AU - Luo, HL
AU - Chen, Yu-Ting
AU - Cheng, YT
AU - Chiang, PH
PY - 2021
Y1 - 2021
N2 - Preserving renal function and controlling oncological outcomes are pertinent when managing renal neoplasms. Cryoablation is the recommended treatment only for clinical T1a stage renal tumour. Here, we compared the outcomes of robot-assisted laparoscopic partial nephrectomy (RaPN) and laparoscopic cryoablation (LCA) in the treatment of patients with localised T1-T2 renal tumours. Overall, 86 patients who received RaPN and 78 patients underwent LCA were included in this study. The intraoperative, postoperative, and oncological outcomes in the LCA group were non-inferior to the RaPN group. Moreover, LCA demonstrated shorter operative time (267.45 ± 104.53 min vs. 138.56 ± 45.28 min, < 0.001), lower blood loss (300.56 ± 360.73 mL vs. 30.73 ± 50.31 mL, < 0.001), and slight renal function deterioration because of the reduced invasiveness, without compromising on the oncological outcomes.
AB - Preserving renal function and controlling oncological outcomes are pertinent when managing renal neoplasms. Cryoablation is the recommended treatment only for clinical T1a stage renal tumour. Here, we compared the outcomes of robot-assisted laparoscopic partial nephrectomy (RaPN) and laparoscopic cryoablation (LCA) in the treatment of patients with localised T1-T2 renal tumours. Overall, 86 patients who received RaPN and 78 patients underwent LCA were included in this study. The intraoperative, postoperative, and oncological outcomes in the LCA group were non-inferior to the RaPN group. Moreover, LCA demonstrated shorter operative time (267.45 ± 104.53 min vs. 138.56 ± 45.28 min, < 0.001), lower blood loss (300.56 ± 360.73 mL vs. 30.73 ± 50.31 mL, < 0.001), and slight renal function deterioration because of the reduced invasiveness, without compromising on the oncological outcomes.
U2 - 10.3390/diagnostics11050759
DO - 10.3390/diagnostics11050759
M3 - Journal Article
C2 - 33922727
SN - 2075-4418
VL - 11
JO - Diagnostics (Basel, Switzerland)
JF - Diagnostics (Basel, Switzerland)
IS - 5
ER -